anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a hypotensive material containing lactic acid fermentation egg white, its manufacturing method, and a food composition and a pharmaceutical composition which have a hypotensive action.  <P>SOLUTION: The hypotensive material contains lactic acid fermentation egg white. The food composition having a hypotensive action contains the lactic acid fermentation egg white. The pharmaceutical composition having a hypotensive action contains the lactic acid fermentation egg white as an active ingredient. The method for manufacturing the hypotensive material comprises a step of adding lactic acid bacteria to an egg white aqueous solution to perform fermentation.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a cosmetic or medicinal composition having inhibitory effects on glucose-6-phosphate dehydrogenase and transition of fat cells, by including a lipid extract from Andiroba. SOLUTION: This cosmetic or medicinal composition is obtained by including a lipid extract from Andiroba (Carapa guianensis Aubl.) at 0.01-100 wt.% based on the total weight of the cosmetic or medicinal composition. The lipid extract is obtained, e.g. by making the nuclei of Andiroba into a paste, subjecting the paste to high temperature treatment, then passing it through a press. The extract may be incorporated with 0.05% BHT as an antioxidant. The extract dose not act on established cellulite, but, suppresses the possibility of cellulite development owing to inhibitory effects on differentiation of fat cell precursor into fat cells.
Participants in the Treatment arm were assigned to read one each day during the two-week trial period. These articles described a personal experience suicide from a first-person perspective, and included positive messages. Before and after reading these articles, participants in the Treatment arm answered brief questions assessing current suicidal thoughts and other constructs. Participants in the Treatment group were administered follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs.
The invention discloses a curcumenol medicament for treating cancer and production method. In the invention, the curcumenol, which is extracted from zedoary turmeric oil and purified, is dissolved in an oil solvent of black currant oil or borage oil. The curcumenol medicament comprises 0.1 to 25 weight percent of curcumenol, 20 to 99.9 weight percent of black currant oil or borage oil, and 0 to 30 percent of auxiliary material. The curcumenol can be dissolved in the oil solvent of black currant oil or borage oil when crystallization does not start or just starts after the curcumenol is purified. The curcumenol is not crystallized any longer, so the medicament can give full play to effect. The crystallized curcumenol is delivered into a high-speed cutting machine to be ground till the particle size is less than 0.1 mu m; and the ground curcumenol is dissolved in the oil solvent and can be made into various tablets, hard capsules, soft capsules, particles, oral liquid and other oral preparations.
Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
The invention discloses a preparation process of ultramicro spirulina powder. The preparation process of the ultramicro spirulina powder comprises the following two steps: (1) directly superfine grinding the spirulina; and (2) uniformly mixing the spirulina water extract and the extracted spirulina residue product to obtain the spirulina powder. The average grain size of the spirulina powder is 200-800 nm. The prescription and the preparation process of the tablet, the capsule and the soft capsule of the ultramicro spirulina powder and the common spirulina powder (less than 100 meshes) are created and researched based on the ultramicro spirulina powder. The additive amount of the auxiliary materials is greatly reduced; by adopting the new preparation molding process, the problems of unreasonable prescription of the current spirulina product, many auxiliary materials, multiple varieties, low purity, tedious production process and low product quality can be solved; and the industrial production speed can be quickened and the production efficiency can be increased. The prepared product is detected. The function test proves that the ultramicro spirulina powder and the common spirulina powder have the radiation-proof effect and liver-protective effect.
Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
There is limited knowledge about the factors that drive gut-liver axis changes after selenium (Se) deficiency-induced gut or liver injuries. Thus, we tested Se deficiency in mice to determine its effects on intestinal bacterial balance and whether it induced liver injury. Serum Se concentration, lipopolysaccharide (LPS) level, and liver injury biomarkers were tested using a biochemical method, while pathological changes in the liver and jejunum were observed via hematoxylin and eosin stain, and a fluorescence spectrophotometer was used to evaluate intestinal permeability. Tight junction (TJ)-related and toll-like receptor (TLR) signaling-related pathway genes and proteins were tested using quantitative polymerase chain reaction, western blotting, immunohistochemistry, and 16S ribosomal ribonucleic acid gene-targeted sequencing of jejunum microorganisms. Se deficiency significantly decreased glutathione peroxidase activity and disrupted the intestinal flora, with the most significant effect being a decrease in Lactobacillus reuteri. The expression of TJ-related genes and proteins decreased significantly with increased treatment time, whereas supplementation with Se, fecal microbiota transplantation, or L. reuteri reversed these decreases. Signs of liver injury and LPS content were significantly increased after intestinal flora imbalance or jejunum injury, and the levels of TLR signaling-related genes were significantly increased. The results indicated that Se deficiency disrupted the microbiota balance, decreased the expression of intestinal TJ factors, and increased intestinal permeability. By contrast, LPS increased due to a bacterial imbalance, which may induce inflammatory liver injury via the TLR4 signaling pathway.
1,192,141. Pyridine derivatives. CIBA Ltd. 3 Sept., 1968 [8 Sept., 1967; 19 July, 1968], No. 41846/68. Heading C2C. Novel compounds of formula in which R 1  and R 2  are aryl and R 3  is pyridyl (the aryl and pyridyl radicals may optionally be substituted) and their acid addition salts are prepared by reducing (a) a compound of formula or (b) a compound of formula wherein one of X 1 , X 2  and X 3  is =O and the other two are each two H atoms and converting the products of (a) and (b) into their acid addition salts if desired. Intermediates isolated are compounds of formula prepared by reacting R 1 N(R 2 )H with acrylonitrile, compounds of formula prepared by reduction of the above nitriles (III) and compounds of Formula (II) prepared by reacting IV with R 3 -CHO. Pharmaceutical compositions comprise a compound (I) or one of its acid addition salts together with a suitable excipient, are administered topically, enterally or parenterally and have anti-inflammatory activity.
Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
Participants received dalbavancin administered intravenously as follows: birth to \< 3 months old and 3 months to \< 6 years old: 22.5 mg/kg (maximum 1500 mg) on Day 1; ≥6 years to 17 years old (inclusive): 18 mg/kg (maximum 1500 mg) on Day 1. Participants aged birth to \< 3 months were not randomized; all received dalbavancin single-dose.
BACKGROUND: Phytophthora root rot, a major constraint in chile pepper production worldwide, is caused by the soil-borne oomycete, Phytophthora capsici. This study aimed to detect significant regions in the Capsicum genome linked to Phytophthora root rot resistance using a panel consisting of 157 Capsicum spp. genotypes. Multi-locus genome wide association study (GWAS) was conducted using single nucleotide polymorphism (SNP) markers derived from genotyping-by-sequencing (GBS). Individual plants were separately inoculated with P. capsici isolates, 'PWB-185', 'PWB-186', and '6347', at the 4-8 leaf stage and were scored for disease symptoms up to 14-days post-inoculation. Disease scores were used to calculate disease parameters including disease severity index percentage, percent of resistant plants, area under disease progress curve, and estimated marginal means for each genotype.
RESULTS: Most of the genotypes displayed root rot symptoms, whereas five accessions were completely resistant to all the isolates and displayed no symptoms of infection. A total of 55,117 SNP markers derived from GBS were used to perform multi-locus GWAS which identified 330 significant SNP markers associated with disease resistance. Of these, 56 SNP markers distributed across all the 12 chromosomes were common across the isolates, indicating association with more durable resistance. Candidate genes including nucleotide-binding site leucine-rich repeat (NBS-LRR), systemic acquired resistance (SAR8.2), and receptor-like kinase (RLKs), were identified within 0.5 Mb of the associated markers.
CONCLUSIONS: Results will be used to improve resistance to Phytophthora root rot in chile pepper by the development of Kompetitive allele-specific markers (KASP®) for marker validation, genomewide selection, and marker-assisted breeding.
Valsartan and Hydrochlorothiazide Tablets, USP are a combination of valsartan, an orally active, specific angiotensin II receptor blocker (ARB) acting on the AT1 receptor subtype, and hydrochlorothiazide, a diuretic.

Valsartan, a nonpeptide molecule, is chemically described as N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-Valine. Its empirical formula is C24H29N5O3, its molecular weight is 435.5, and its structural formula is

Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water.

Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.

Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C7H8ClN3O4S2, its molecular weight is 297.73, and its structural formula is

Valsartan and Hydrochlorothiazide Tablets, USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, USP 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.
A tissue engineering scaffold for growing cells can include a plurality of biocompatible microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have a first characteristic, and a first predetermined spatial distribution with respect to the three-dimensional matrix. The second set of microspheres can have a second characteristic that is different from the first characteristic, and a second predetermined spatial distribution that is different from the first predetermined spatial distribution with respect to the three - dimensional matrix. The first and second characteristics can selected a composition, polymer, particle size, particle size distribution, type of bioactive agent, type of bioactive agent combination, bioactive agent concentration, amount of bioactive agent, rate of bioactive agent release, mechanical strength, flexibility, rigidity, color, radiotranslucency, radiopaqueness, or the like.
Delirium is a neuropsychiatric disorder with a sudden and reversible decline in attention and cognition due to a medical condition.8 Delirium is associated with emotional distress for patients, their relatives and medical staff.3-5 During delirium, patients are at risk of severe harm due to unattended bed-exits and subsequent falls.6, 7 As worldwide strategy, sitters are used for the prevention of harm in patients with delirium. However, evidence of the effectiveness of sitters is scant.9 A newly designed specialised acute care unit for older patients with delirium, the FELIX PLATTER delirium unit (DelirUnit), strives to overcome the aforementioned shortcomings. On the DelirUnit there are no physical barriers such as bed rails to prevent patients from bed-exits. Floor beds minimize injuries when patients leave their beds unattended. Specialised nurses and nursing aides care for this vulnerable patient group. Sitters are banned. As an alternative to sitters, nurses are informed about patients' intended bed-exit by electronic alarming contact mats at the bedside or in front of beds (CareMat®) or by a novel contactless radar-based bed-exit monitoring system (Qumea®). Up until now, evidence for the effectiveness of technical devices for fall risk prevention is low. This research intends to explore how effective contact mats (CareMat®) or contactless bed-exit alarming devices (Qumea®) are in fall risk detection and fall prevention.
In Finland, the aim is to reduce the institutional care of older people and caring them in their own homes. The goal of shifting the focus of services to open services is difficult to implement if the health of the caregivers is inadequate. In order to achieve this goal, it is important to influence the health and performance of caregivers. Information is needed to support this, among others, about how the nutrition and oral health of caregivers can be promoted and to what extent this affects the performance and quality of life of their clients. A randomly of 220 caregivers over 65 years old and their clients is selected for this study. The caregivers are randomized to either treatment or control groups. At the beginning of the study is estimated the nutritional status and oral health of the caregivers. Based on the results, the nutritionist and dental hygienist give individual advice to optimize the nutrition and oral health of the caregivers in the intervention group. After six months, the same measurements are made as at the beginning of the study. Monitoring measurements will be made one year after the start of the intervention. The results of this project provide information on the health, well-being, and ability to the function of the caregivers. Based on the results, is developed an operating model that is intended to be wide as use as possible. Improving the nutrition and oral health of caregivers has a significant impact on their own and their clients health and well-being as well as the long-term care costs presumably.
Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
The purpose of the study is to investigate the role of paternal exposures in the etiology of sporadic heritable retinoblastoma (RBL). The study has a matched case-control design with a sample size of 255 pairs. Cases will be children with sporadic heritable (RBL) identified from eight hospitals that together treat most of the RBL patients in the U.S. and Canada. We will use regional controls matched on year of birth and state/province of residence identified by randomdigit-dialing (RDD). Fathers and mothers of cases and controls will be interviewed by telephone about their occupational, medical, dietary, and personal exposures before the index child's conception. Blood samples will be obtained on cases and their parents for DNA isolation. The case's DNA will be used to characterize the disease-causing RB1 mutation. The parent's DNA will be used to detect the few instances in which a parent also has the RB1 mutation, i.e., the child's RBL is familial rather than sporadic.
We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2 (HSV2), or other virus), or a bacterial infection (such as  Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl,  or  Chlamydia trachomatis,  or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.
Epoxy resin-based dental protheses, immediately usable in the mouth, are prepd. by partially polymerising a mixture contng. an epoxy compd. and a hardener, in general an amine, before application in the mouth. The mixture is easily worked onto the teeth to be treated, and its polymsn. is completed spontaneously within several minutes. The protheses obtd. have excellent adherence, excellent dimensional stability etc. The polymsn. can be stopped at the desired time and the viscous mass obtd. can be applied without haste, and hardening of the mass in the mouth is extremely rapid.
The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR 4  gene are determined in a patient suffering from a hyperproliferative disorder, e.g. cancer. Based on the results of this determination and the status of the disorder to be treated a therapeutic protocol may be developed. Yet another subject of the present invention is a screening method.
NEW MATERIAL:A compound expressed by formula I (X is organic or inorganic acid residue). EXAMPLE:N-Phenyl-4-guanidinomethylbenzamide hydrochloride monohydrate. USE:An antiulcer agent. PREPARATION:A 4-guantidinomethylbenzoic acid expressed by formula II and aniline expressed by formula III are subjected to condensation reaction through dehydration in the presence of dicyclohexylcarbodiimide (hereinafter abbreviated to DCC) in a solvent and, as necessary, the resultant free product is converted into a salt, etc., to afford the aimed compound expressed by formula I. The reaction is carried out by using the compound expressed by formula III in an amount of 1.0-1.5 mol based on 1.0 mol compound expressed by formula I and DCC in an amount of 1.0-1.5 mol based on 1.0 mol compound expressed by formula II. Preferred reaction solvents are anhydrous acetone, THF, dioxane, pyridine, etc.
A method, a system, and a computer-readable medium are provided for generating a complex alert. Values of a plurality of physiological characteristics of a patient are received. The received values are compared to a complex alert rule associated with a medical condition. The complex alert rule includes a plurality of alert rules, wherein each alert rule includes an indicator of a physiological characteristic of a patient associated with the alert rule and a condition priority associated with an urgency of the alert rule. The complex alert rule also includes a trigger rule. The trigger rule includes a plurality of rules wherein each rule includes a number of satisfied alert rules for each value of the condition priority. A number of alert rules of the plurality of alert rules that are satisfied is determined for each condition priority of the complex alert rule based on the comparison. A complex alert is generated if the determined number of alert rules for a condition priority satisfies the trigger rule of the complex alert rule.